COVID Neuropathy: Nerve Damage, Signs, and Recovery

COVID-19 can damage peripheral nerves through several distinct pathways, from direct viral invasion and immune-system overreaction to physical compression during intensive care. The most commonly reported form in people with lingering symptoms is small fiber neuropathy, a condition affecting the thin nerve endings in skin and organs that control pain sensation and automatic body functions. But the nerve damage linked to COVID is not one condition; it spans a range of problems with different causes, timelines, and prospects for recovery.

How COVID-19 Gets to Your Nerves

The virus behind COVID-19 is best known for attacking the lungs, but research has shown it can reach the nervous system as well. Pain-sensing neurons in the dorsal root ganglia, clusters of nerve cell bodies that sit alongside the spinal cord and relay signals from the body to the brain, express the ACE2 receptor that SARS-CoV-2 uses to enter cells. Specifically, ACE2 appears on a subset of nociceptors whose free nerve endings extend into the outermost layers of skin and the lining of internal organs, which means the virus could potentially enter the peripheral nervous system through those exposed nerve tips.¹

Direct viral invasion, though, is likely only part of the story. In many patients the nerve damage appears weeks after the initial infection has cleared, pointing to an immune-mediated process rather than ongoing viral replication. The immune system, primed to fight the virus, may mistakenly target nerve tissue. Inflammation from the acute infection can also injure nerves indirectly, and people who spend extended time in the ICU face additional risks from positioning, prolonged sedation, and the body’s systemic response to critical illness. These different mechanisms explain why COVID-related nerve problems look so varied from person to person.

Small Fiber Neuropathy and Long COVID

Among people with prolonged post-COVID symptoms, small fiber neuropathy (SFN) is the nerve condition that keeps turning up. Small fibers are the thinnest peripheral nerves, responsible for pain and temperature sensation as well as autonomic functions like sweating, heart rate control, and digestion. When they are damaged, the result is often burning pain, tingling, and numbness in the hands and feet, along with a cascade of problems in body systems you normally do not have to think about.

A study of 17 long-COVID patients who underwent formal neuropathy testing found that roughly 59% had at least one test confirming neuropathy. Skin biopsy, the most sensitive tool for detecting small fiber damage, was abnormal in about 63% of those tested, while standard electrodiagnostic tests (which mainly pick up large-fiber problems) caught abnormalities in only about 17%.² That gap is telling. It means that many people with genuine nerve damage after COVID will get normal results on a standard nerve conduction study, because the damage is concentrated in fibers too small for those tests to detect.

A systematic review of post-COVID SFN found that the condition often begins with burning pain and numbness in the distal limbs and can involve multiple organ systems, including cognitive, visual, and autonomic symptoms. The severity of SFN symptoms did not necessarily track with how bad the original COVID infection was; even people with mild acute illness developed significant neuropathy afterward.³ That disconnect frustrates patients and doctors alike, because it means you cannot predict who will develop nerve problems based on how sick they were initially.

What the Symptoms Feel Like

The hallmark of COVID-related neuropathy is neuropathic pain, a distinctive type of pain that feels like burning, electric shocks, or stabbing sensations rather than the dull ache of a muscle injury. One documented case involved a patient who developed severe burning pain affecting his entire body within a week of testing positive, which then settled into the hands and feet. Standard nerve conduction tests and even skin biopsy came back normal in that case, yet the pain was real and debilitating enough to require steroids for relief.⁴

In a larger study of over 200 post-COVID patients screened with validated pain questionnaires, around 3 to 6% met criteria for neuropathic pain depending on which scoring tool was used. The most common painful areas were the back, low back, and knees, and the intensity of pain during the acute COVID illness was a predictor of developing neuropathic pain afterward.⁵ While those percentages sound modest, they represent a significant number of people when applied to the hundreds of millions who have had COVID worldwide.

Beyond pain and numbness, nerve damage after COVID frequently produces symptoms people may not immediately connect to their nerves:

Heart rate swings: Feeling your heart race when you stand up or experiencing lightheadedness upon rising from a chair.
Temperature regulation problems: Sweating too much or too little, or feeling alternately flushed and cold.
Digestive disruption: Nausea, bloating, or erratic bowel function without an obvious gastrointestinal cause.
Cognitive difficulties: “Brain fog” that accompanies small fiber damage, possibly related to reduced blood flow regulation in the brain.

Autonomic Dysfunction and POTS

The autonomic symptoms deserve their own attention because they are among the most disabling and least understood consequences of COVID-related nerve damage. Autonomic nerves regulate all the bodily functions you do not consciously control, from blood pressure adjustments when you stand to the speed at which your stomach empties food. When small fibers controlling these functions are damaged, the result is dysautonomia, a broad term for the nervous system failing to manage these automatic processes properly.

Postural orthostatic tachycardia syndrome, commonly known as POTS, has emerged as the most common autonomic pattern among post-COVID patients. In POTS, standing up triggers an excessive heart rate increase, often accompanied by dizziness, fatigue, and sometimes fainting. A narrative review in Frontiers in Neurology estimated that late-onset dysautonomia occurs in about 2.5% of people with post-COVID conditions, with POTS being the dominant presentation.⁶

For someone who was previously healthy and active, developing POTS after a viral infection can be life-altering. Simple tasks like showering, standing in a grocery store line, or walking up a flight of stairs may trigger symptoms. Because the condition involves invisible nerve damage rather than something visible on an X-ray, patients often face skepticism before getting a diagnosis.

Guillain-Barré Syndrome After COVID

Guillain-Barré syndrome (GBS) is the most dramatic form of nerve damage associated with COVID-19. Unlike the gradual onset of small fiber neuropathy, GBS hits fast: the immune system attacks the myelin sheath insulating peripheral nerves, causing rapid-onset weakness that typically starts in the legs and can spread upward. In severe cases, it affects the muscles used for breathing.

A systematic review of 436 COVID-associated GBS cases found that neurological symptoms began an average of 19 days after the first COVID symptom.⁷ That roughly three-week delay is consistent with how GBS develops after other infections: the immune system builds an antibody response to the pathogen, and those antibodies cross-react with nerve tissue. GBS is not new to COVID; it has long been linked to infections like Campylobacter and influenza. But the sheer number of COVID infections worldwide brought a wave of associated GBS cases that drew intense research attention.

A large multinational study comparing the risk of GBS after both vaccination and SARS-CoV-2 infection found that actual COVID-19 infection carried a meaningful GBS risk, with a relative incidence of about 3.35. Among vaccines, the adenoviral-vector vaccine (Vaxzevria/Covishield) showed an elevated risk as well, while the mRNA vaccine (Comirnaty) was actually associated with a decreased risk of GBS.⁸ In practical terms, the infection itself was a bigger GBS risk than most vaccines used to prevent it.

Not all post-COVID GBS cases are severe. A case report described a 9-year-old boy who developed unbalanced gait, back pain, and lower limb weakness after COVID, with examination and spinal fluid findings consistent with GBS. He recovered over 8 to 12 weeks with conservative management alone, without needing immunotherapy.⁹ This does not mean GBS should be taken lightly, since severe cases require hospitalization and sometimes ventilator support, but it illustrates the wide spectrum of outcomes.

Nerve Injuries from ICU Care

There is a category of COVID-related nerve damage that has nothing to do with the virus itself and everything to do with how severely ill patients are treated. During the pandemic, patients with acute respiratory distress syndrome (ARDS) were frequently placed in a prone position, lying face down, to improve oxygenation. While this positioning saved lives, it also put sustained pressure on peripheral nerves, especially in the arms.

A study from one rehabilitation facility found that about 14.5% of patients admitted after COVID-related ARDS were diagnosed with peripheral nerve injuries, and nearly all of them had undergone prone positioning. Across those patients, upper-limb injuries dominated, with the ulnar nerve being the most frequently affected, followed by the radial and sciatic nerves.¹⁰ A multicenter case series of patients with upper extremity nerve problems after severe COVID noted that the median duration of mechanical ventilation was 39 days, and over half had undergone prone positioning.¹¹

An imaging review categorized the mechanisms of peripheral nerve injury in COVID patients into four buckets: post-infectious inflammatory neuropathy, positioning-related stretch and compression, systemic neuropathy from critical illness, and nerve entrapment caused by hematomas from blood-thinning medications commonly used in the ICU.¹² Recognizing that some nerve injuries after COVID are iatrogenic, meaning caused by treatment rather than the disease, matters because the recovery timeline and approach differ from immune-mediated damage.

Loss of Smell as a Form of Nerve Damage

The sudden loss of smell that became almost synonymous with COVID-19 is itself a form of nerve-related damage, though its mechanism turned out to be more surprising than initially assumed. Early in the pandemic, many suspected the virus was directly infecting olfactory neurons. Research clarified that SARS-CoV-2 primarily attacks sustentacular cells, the support cells in the olfactory epithelium, rather than the neurons themselves.¹³

The downstream effect on neurons, however, is real. A study published in Cell showed that SARS-CoV-2 infection causes widespread downregulation of olfactory receptors in neurons the virus cannot even directly infect. The mechanism involves a dramatic reorganization of the nuclear architecture within those neurons, disrupting the genomic compartments where olfactory receptor genes are housed.¹⁴ In simpler terms, the virus damages the neighborhood around the olfactory neurons badly enough that the neurons shut down their smell-detecting machinery even though they were never directly invaded. For most people, smell recovers within weeks to months, but a minority experience prolonged or permanent changes, sometimes including parosmia, where familiar smells become distorted and unpleasant.

Getting a Diagnosis

One of the biggest frustrations for people with suspected post-COVID neuropathy is that standard neurological testing often comes back normal. As the long-COVID evaluation study showed, electrodiagnostic tests, which measure the speed and strength of electrical signals in larger nerves, caught problems in only about 17% of patients, while skin biopsy found abnormalities in 63%.² This discrepancy exists because COVID-related neuropathy is predominantly a small-fiber problem, and standard nerve conduction studies are designed to assess large fibers.

A systematic review of electrophysiological assessments in COVID-related neuropathy found that among patients who did undergo nerve conduction studies and electromyography, abnormal motor nerve conduction appeared in about 31% and abnormal EMG in about 25%, while sensory nerve conduction was abnormal in only 4%. The tibial and peroneal nerves in the legs and the ulnar nerve in the arms were the most frequently affected on testing. The condition was characterized as a demyelinating motor neuropathy when large fibers were involved.¹⁵

For suspected small fiber neuropathy, the systematic review of post-COVID SFN identified skin biopsy as the gold standard diagnostic tool, with corneal confocal microscopy useful when eye discomfort is part of the picture. Other useful complementary tests include quantitative sensory testing and autonomic function tests.³ If you are experiencing symptoms consistent with neuropathy after COVID and your initial nerve conduction study was normal, asking specifically about a skin biopsy or autonomic testing is worth the conversation with your neurologist.

Treatment Options

There is no single treatment that reverses COVID-related nerve damage. Management focuses on controlling symptoms, especially pain, while giving the nerves time to heal. The pharmacological approach mirrors how neuropathic pain from other causes is treated, adapted to the individual patient’s symptom profile.

First-line medications typically include gabapentinoids like pregabalin or gabapentin, tricyclic antidepressants like amitriptyline, and serotonin-norepinephrine reuptake inhibitors (SNRIs). Topical treatments such as lidocaine patches and capsaicin patches can help when pain is localized. For trigeminal nerve pain specifically, carbamazepine is often tried first. When first-line options are not sufficient, the ladder extends to other anticonvulsants and, in refractory cases, stronger analgesics including tramadol.¹⁶ A narrative review in Pain and Therapy also noted that non-pharmacological approaches, including invasive and noninvasive neurostimulation techniques, can be part of the toolkit for refractory neuropathic pain.¹⁷

For GBS, standard treatments are intravenous immunoglobulin (IVIG) and plasma exchange, the same therapies used for GBS from any cause. These aim to tamp down the autoimmune attack on the nerve sheath. Some clinicians have also explored IVIG for post-COVID small fiber neuropathy when an autoimmune component is suspected, though evidence for that application is still emerging.

Physical therapy plays an important role in recovery across all forms of COVID neuropathy. A systematic review found that physical therapy was identified as a crucial part of managing long COVID, with positive outcomes for improving symptoms and overall physical function.¹⁸ For people with autonomic dysfunction, exercise programs need to be carefully graded to avoid triggering symptom flares, often starting with reclined or seated exercises before progressing to upright activity.

What Recovery Looks Like

Recovery from COVID-related neuropathy varies enormously depending on the type and severity of nerve damage. Peripheral nerves, unlike those in the brain and spinal cord, can regenerate, but they do so slowly, typically at a rate of about an inch per month. For small fiber neuropathy, improvement may take months to more than a year, and some patients experience lasting symptoms even as objective measures of nerve fiber density slowly improve.

GBS recovery tends to follow a more predictable arc. Most patients begin improving within weeks of the immune attack subsiding, though full recovery can take six months to two years. Some are left with residual weakness or sensory changes. The pediatric case described earlier, where a child recovered in 8 to 12 weeks without immunotherapy, represents the favorable end of the spectrum.⁹

Compression neuropathies from prone positioning in the ICU generally have a better prognosis than immune-mediated damage, because the nerve is structurally intact and just needs time to recover from being compressed. Many of these injuries improve substantially over weeks to months with physical therapy and activity modification, though severe cases where the nerve fiber was badly damaged can leave lasting deficits.

For autonomic dysfunction, recovery is particularly unpredictable. Some people with post-COVID POTS see significant improvement within a year; others develop a chronic condition that requires ongoing management with hydration strategies, compression garments, medications to stabilize heart rate, and gradual reconditioning programs.

Diabetes and Other Risk Amplifiers

Pre-existing diabetes substantially raises the stakes. People with diabetes already have nerves that are stressed by high blood sugar levels, and the added inflammation from COVID-19 can push those nerves past a tipping point. A case report documented a patient in whom COVID-19 infection, combined with type 2 diabetes and its associated chronic low-grade inflammation, precipitated diabetic neuropathy.¹⁹ COVID itself can also destabilize blood sugar control, creating a vicious cycle where hyperglycemia worsens nerve damage and nerve damage impairs the autonomic regulation of metabolism.

Children are not immune to post-COVID nerve complications, though they appear to be affected less frequently than adults. A scoping review of post-acute COVID sequelae in pediatric patients in the United States documented cases of GBS, progressive limb weakness, and other neurological complications including one 12-year-old who became bed-ridden after developing progressive weakness and delirium following SARS-CoV-2 infection.²⁰ These cases remain rare in children, but they underscore that COVID neuropathy is not exclusively an adult problem.

When Normal Tests Do Not Mean Normal Nerves

Perhaps the most important practical takeaway for anyone dealing with nerve symptoms after COVID is that a normal nerve conduction study does not rule out neuropathy. The tools most commonly available in neurology clinics are calibrated to detect damage in large myelinated nerve fibers, the ones that control muscle strength and deep sensation. They are essentially blind to the small unmyelinated and thinly myelinated fibers that carry pain signals and regulate autonomic functions, which are exactly the fibers most often damaged by COVID.

This creates a real-world problem. Patients experience debilitating burning pain, numbness, racing heart rates, and digestive problems, get an EMG and nerve conduction study that looks clean, and are told nothing is wrong with their nerves. The evidence consistently shows that skin punch biopsy, which directly counts the density of small nerve fibers in a tiny sample of skin, is a far more sensitive test for the type of neuropathy COVID tends to cause. Autonomic function testing, which measures how well the nervous system regulates sweating, blood pressure, and heart rate responses, provides another diagnostic window. If your symptoms are consistent with small fiber neuropathy and standard electrical tests have been unrevealing, these additional evaluations are the logical next step to pursue with a specialist familiar with post-COVID neurological complications.

1
PubMed Central. ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects
2
PubMed Central. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID
3
PubMed Central. Post-COVID-19 Small Fiber Neuropathy as a New Emerging Quality of Life-Threatening Disease: A Systematic Review
4
PubMed Central. Neuropathic pain post-COVID-19: a case report
5
PubMed Central. Neuropathic pain in patients with post-COVID-19
6
PubMed Central. Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies
7
PubMed Central. Guillain–Barré syndrome associated with COVID-19: A systematic review
8
PubMed. Risk of Guillain-Barré syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study
9
BMJ Case Reports. Guillain-Barre syndrome (GBS) associated with COVID-19 infection that resolved without treatment in a child
10
PubMed Central. Injury-prone: peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome
11
PubMed Central. Upper Extremity Neuropathies Following Severe COVID-19 Infection: A Multicenter Case Series
12
PubMed Central. Imaging Review of Peripheral Nerve Injuries in Patients with COVID-19
13
PubMed Central. Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection
14
PubMed Central. Non-cell-autonomous disruption of nuclear architecture as a potential cause of COVID-19-induced anosmia
15
PubMed Central. Electrophysiological assessment in patients with COVID-19-related peripheral neuropathies and myopathies: a systematic review
16
PubMed Central. Pharmacological Proposal Approach to Managing Chronic Pain Associated with COVID-19
17
PubMed Central. Pain Management in the Post-COVID Era—An Update: A Narrative Review
18
PubMed Central. Long COVID and Physical Therapy: A Systematic Review
19
PubMed Central. COVID-19 is associated with high blood glucose levels: diabetic neuropathy during the SARS-CoV-2 pandemic: a case report
20
American Journal of Medicine Open. Review Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review